Hostname: page-component-848d4c4894-tn8tq Total loading time: 0 Render date: 2024-07-05T12:24:42.354Z Has data issue: false hasContentIssue false

Impact of adapted physical activity on hippocampal N-Acetyl Aspartate in patients with schizophrenia

Published online by Cambridge University Press:  19 July 2023

L. Metivier*
Affiliation:
Calvados, Normandie Univ, UNICAEN, PhIND, UMR-S 1237, GIP CYCERON, Caen
F. Briend
Affiliation:
Indre et Loire, UMR Inserm U 1253 – iBrain – Psychiatrie Neuro-Fonctionelle – Equipe 1, Tours
M. Tréhout
Affiliation:
Calvados, Normandie Univ, UNICAEN, PhIND, UMR-S 1237, GIP CYCERON, Caen Calvados, CHU de CAEN Normandie, Service de Psychiatrie, Centre Esquirol
L. Bigot
Affiliation:
Calvados, Mooven
G. Quarck
Affiliation:
Calvados, Normandie Univ, UNICAEN/INSERM, UMR 1075, COMETE, PFRS, Caen
A. Herbinet
Affiliation:
Hérault, CSO, Mooven, Saint-Mathieu-de-Treviers, France
E. Leroux
Affiliation:
Calvados, Normandie Univ, UNICAEN, PhIND, UMR-S 1237, GIP CYCERON, Caen
S. Dollfus
Affiliation:
Calvados, Normandie Univ, UNICAEN, PhIND, UMR-S 1237, GIP CYCERON, Caen Calvados, CHU de CAEN Normandie, Service de Psychiatrie, Centre Esquirol
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Adapted physical activity (APA) has beneficial neurobiological impact but the underlying pathophysiological mechanisms remain poorly described. APA is currently recognized as an adjuvant therapy to antipsychotic treatments in patients with schizophrenia (SCZs) to reduce the severity of negative symptoms and cognitive impairment. SCZs exhibit hippocampal N-acetylaspartate (NAA) reduction, a marker of neuronal viability and integrity whose concentrations can be assessed by proton magnetic resonance spectroscopy (1H-MRS).

Objectives

The purpose of this study was to evaluate the impact of remote physical activity (e-APA) via the web on the NAA relative variations in the left hippocampus in SCZs compared to a patient control group benefiting from an health education program (HE). This study concerns one of the secondary objectives of the PEPsy V@SI study co-financed by the Pierre Deniker Foundation, the European Union and the Normandy Region within the framework of the FEDER/FSE 2014-2020 operational program.

Methods

Thirty-five SCZs were randomized in the e-APA active group or in the control group (HE). Participants received the interventions during 16 weeks, with two visioconference sessions per week. A 1H-MRS sequence positioned on the left hippocampus (MRI-3T) was acquired before and after both interventions. Absolute NAA concentrations in the left hippocampus were obtained using Osprey software after partial volume correction. After checking the quality criteria, the spectra of 6 SCZs in the e-APA group and 8 SCZs in the HE group were analyzed. To test the difference between interventions on the NAA relative variations, a Wilcoxon-Mann-Whitney test and effect size were performed. Paired Wilcoxon tests were used in each group before and after the interventions.

Results

No significant difference was found in NAA relative variations in the left hippocampus between the e-APA group and the HE group (p = 0.18), although the effect size was 0.38 (considered as moderate). However, a trend towards an increase of NAA was observed in the e-APA group (before intervention: 12.08 International Units (I.U); after: 13.81 I.U) (p = 0.06) but not in the HE group (before intervention: 13.75 I.U ; after: 13.85 I.U) (p = 0.84).

Conclusions

Our results showed a NAA significant increase in SCZs after an e-APA program, indicating a beneficial impact of e-APA on neuronal viability that might reflect an hippocampal plasticity. However, this increase did not differ significantly between active and control groups probably due to a weak statistical power.

Disclosure of Interest

L. Metivier: None Declared, F. Briend: None Declared, M. Tréhout: None Declared, L. Bigot: None Declared, G. Quarck: None Declared, A. Herbinet: None Declared, E. Leroux: None Declared, S. Dollfus Consultant of: Fabre,Gedeon,Roche and Takeda, inivited Conferences by Lundbeck, Otsuka, Janssen ; at contracts with Prophase MedAvances and NeuroCogTrials

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.